Sebia is a global specialized In Vitro Diagnostic player providing equipment and reagents for the screening and monitoring of various diseases, primarily in the areas of Oncology (Multiple Myeloma), Diabetes, Hemoglobinopathy, autoimmunity and other rare pathologies. Sebia is continuously investing in innovations dedicated to Multiple Myeloma with HYDRASHIFT, Sebia FLC Kappa/ Lambda assays and Clonotypic Peptides Mass spectrometry for MRD testing on blood.